The Alliance for Clinical Trials in Oncology has launched a new clinical trial for adults who need first-line therapy for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The ...

Researchers assessed whether venetoclax-obinutuzumab would be safe and effective in fit and unfit patients with previously untreated CLL.

BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...

The Inflation Reduction Act introduced Medicare drug price negotiations to reduce treatment costs, enhance access, and ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, ...

Genmab’s analyst fair value estimate has been adjusted from DKK 2,182.25 to DKK 2,237.63, while some bullish price targets now cluster in the DKK 2,400 to DKK 2,500 range and around US$40 to US$41.50.

TD Cowen 46th Annual Health Care Conference March 3, 2026 1:50 PM ESTCompany ParticipantsCaroline Litchfield - Executive ...

In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.

By Sneha S K March 9 (Reuters) - Bristol Myers Squibb on Monday said its experimental drug for a rare form of blood cancer ...

Women with stage IV breast cancer detected through screening have a 60% chance of survival 10 years after diagnosis. This is in comparison to a survival rate of under 20% of those with stage IV breast ...

Dr. Nicoletta Colombo breaks down KEYNOTE B96 showing Keytruda plus paclitaxel, with or without bevacizumab, improves ...